Janjigian, Yelena Y.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 4,071

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 3,380

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 710

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research

Hepatocellular Carcinoma Treatment and PrognosisCancer Genomics and Diagnostics

Cited by 602

Gastric adenocarcinoma

Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers

Gastric Cancer Management and OutcomesHelicobacter pylori-related gastroenterology studies

Cited by 594

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations

Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 362

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., et al. (2020) · Annals of Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 208

PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis

Yamaguchi, N., Weinberg, E. M., Nguyen, A., Liberti, M. V., Goodarzi, H., Janjigian, Y. Y., Paty, P. B., Saltz, L. B., Kingham, T. P., Loo, J. M., et al. (2019) · eLife

Cancer, Hypoxia, and MetabolismBiochemical and Molecular Research

Cited by 91

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients

Epstein, A. S., Volandes, A. E., Chen, L. Y., Gary, K. A., Li, Y., Agre, P., Levin, T. T., Reidy, D. L., Meng, R. D., Segal, N. H., et al. (2013) · Journal of Palliative Medicine

Palliative Care and End-of-Life IssuesCardiac Arrest and Resuscitation

Cited by 91

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

Mondaca, S., Margolis, M., Sanchez-Vega, F., Jonsson, P., Riches, J. C., Ku, G. Y., Hechtman, J. F., Tuvy, Y., Berger, M. F., Shah, M. A., et al. (2019) · Gastric Cancer

Gastric Cancer Management and OutcomesHER2/EGFR in Cancer Research

Cited by 21